MyMSTeam

Both Kesimpta and Ocrevus are treatments for multiple sclerosis, but they have some differences:

Kesimpta (Ofatumumab)
- Type: Biologic immunomodulator, CD20-directed cytolytic antibody
- Administration: Injection under the skin using a prefilled pen or syringe.
- Common Side Effects: Headache, injection site irritation, Show Full Answer

Both Kesimpta and Ocrevus are treatments for multiple sclerosis, but they have some differences:

Kesimpta (Ofatumumab)
- Type: Biologic immunomodulator, CD20-directed cytolytic antibody.
- Administration: Injection under the skin using a prefilled pen or syringe.
- Common Side Effects: Headache, injection site irritation, injection-related reactions, upper respiratory tract infection.
- Serious Side Effects: Opportunistic infections, fetal harm.
- Mechanism: Reduces the number of CD20-positive B cells involved in relapsing multiple sclerosis.

Ocrevus (Ocrelizumab)
- Type: Biologic immunomodulator, genetically engineered antibody.
- Administration: Intravenous infusion in a medical setting once every six months after initial loading doses.
- Common Side Effects: Infusion reactions, headache.
- Mechanism: Reduces the number of CD20-positive B cells involved in nerve cell attacks.

Consult your healthcare provider to determine which treatment is best for your specific condition.

 AI-generated responses are not a substitute for medical advice. These services are not intended to diagnose, treat, or cure any condition or disease. Always ask your doctor about specific health concerns.

Kesimpta (Ofatumumab) for Multiple Sclerosis | MyMSTeam

Ocrevus (Ocrelizumab) for Multiple Sclerosis | MyMSTeam